Literature DB >> 32158092

Health-Related Quality of Life and Burden of Fatigue in Chinese Patients with Immune Thrombocytopenia: A Cross-Sectional Study.

Ran Yang1, Hao Yao1, Lin Lin1, Jian-Min Ji1, Qun Shen1.   

Abstract

To describe the health-related quality of life (HRQoL) and fatigue burden among adult patients with immune thrombocytopenia (ITP) in China and determine whether they vary with disease phase. This is a cross-sectional, multi-centre observational study of adult ITP patients and the general population. Participants completed the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). We compared HRQoL and fatigue between ITP patients and the general population, overall and by disease phase (newly diagnosed, persistent, and chronic), using propensity score matching. 203 Patients and 269 members of the general population were recruited. Thirty-six ITP patients (17.7%) were newly diagnosed, 46 (22.7%) were persistent, and 121 (59.6%) were chronic. Compared with the general population, ITP patients had impaired HRQoL and greater fatigue burden. The persistent ITP group showed the largest number of SF-36 scales exceeding the minimally important difference: physical functioning [- 10.5; 95% confidence interval (CI) - 24.5 to 3.5; P < 0.001], role physical (- 16.7; 95% CI - 36.4 to 3.0; P < 0.001), social functioning (- 15.6; 95% CI - 34.5 to 3.3; P < 0.001), and role emotional (- 12.1; 95% CI - 26.0 to 1.8; P < 0.001). Chronic ITP patients had the worst FACIT-F scores (36.89 ± 5.21). Higher fatigue severity was associated with lower physical and mental HRQoL. The HRQoL and fatigue burden of Chinese adult patients with ITP vary by disease phase. Persistent ITP patients were the most vulnerable subgroup in terms of HRQoL, while chronic ITP patients bear the heaviest fatigue burden. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Fatigue; Functional assessment of chronic illness therapy-fatigue; Health-related quality of life; Immune thrombocytopenia; Short form-36

Year:  2019        PMID: 32158092      PMCID: PMC7042440          DOI: 10.1007/s12288-019-01124-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  17 in total

1.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

2.  Patient reported outcome measures: a model-based classification system for research and clinical practice.

Authors:  Jose M Valderas; Jordi Alonso
Journal:  Qual Life Res       Date:  2008-10-03       Impact factor: 4.147

3.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: reply.

Authors:  C Neunert; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-06-19       Impact factor: 5.824

Review 4.  Pathogenesis of immune thrombocytopenia.

Authors:  Sylvain Audia; Matthieu Mahévas; Maxime Samson; Bertrand Godeau; Bernard Bonnotte
Journal:  Autoimmun Rev       Date:  2017-04-17       Impact factor: 9.754

Review 5.  Fatigue in immune thrombocytopenia.

Authors:  Quentin A Hill; Adrian C Newland
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

6.  Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.

Authors:  F Efficace; M Baccarani; M Breccia; F Cottone; G Alimena; G L Deliliers; C Baratè; G Specchia; R Di Lorenzo; L Luciano; D Turri; B Martino; F Stagno; M Dabusti; M Bergamaschi; P Leoni; M P Simula; L Levato; C Fava; D Veneri; S Sica; A Rambaldi; G Rosti; M Vignetti; F Mandelli
Journal:  Leukemia       Date:  2013-02-18       Impact factor: 11.528

7.  Fatigue in adult patients with primary immune thrombocytopenia.

Authors:  Julia L Newton; Jessica A Reese; Shirley I Watson; Sara K Vesely; Paula H B Bolton-Maggs; James N George; Deirdra R Terrell
Journal:  Eur J Haematol       Date:  2011-03-23       Impact factor: 2.997

Review 8.  Second-line therapies in immune thrombocytopenia.

Authors:  Rachael F Grace; Cindy Neunert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

9.  Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey.

Authors:  Claire F Snyder; Susan D Mathias; David Cella; John J Isitt; Albert W Wu; Joan Young
Journal:  Curr Med Res Opin       Date:  2008-08-19       Impact factor: 2.580

10.  Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Authors:  Abderrahim Khelif; Mansoor N Saleh; Abdulgabar Salama; Maria do Socorro O Portella; Mei Sheng Duh; Jasmina Ivanova; Kelly Grotzinger; Anuja N Roy; James B Bussel
Journal:  Am J Hematol       Date:  2018-11-29       Impact factor: 10.047

View more
  1 in total

1.  Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.

Authors:  Alicia Rovó; Nathan Cantoni; Kaveh Samii; Axel Rüfer; Giedre Koenen; Sandra Ivic; Davide Cavanna; Rudolf Benz
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.